In-depth guide detailing the entire drug discovery process

Molecular Targeted Drug Discovery covers the practice of drug discovery against specific molecular targets, beginning with a history of the development of medicine as a molecular science and introducing the reader to the various therapeutic modalities that are in current clinical use against molecular targets. Subsequent chapters cover each of the sequential stages of drug discovery from target selection through declaration of a clinical candidate molecule as well as cutting-edge technologies and methodologies.

The book includes real-life case studies and examples, making complex concepts accessible and engaging, and uses language and approaches for a range of scientific backgrounds, easing communication and solving an important efficiency hurdle in the drug discovery process.

Molecular Targeted Drug Discovery discusses:

• The history of pharmacology and medicine as molecular sciences
• The molecular basis of diseases, including genetic alterations, gene amplification, protein overexpression, synthetic lethality, and disease association versus causality
• Therapeutic modalities for target-specific modulation, covering both biologics and small molecule drug approaches
• The stages of modern drug discovery from target selection and hit finding through lead optimization and structure-activity relationship studies

Molecular Targeted Drug Discovery is an excellent resource for early career practitioners in pharmaceutical research and drug discovery, graduate students in related programs of study, and researchers in drug discovery, chemical and physical sciences, pharmacology, biological sciences, and medicine.

ROBERT A. COPELAND, Ph.D. is a biomedical sciences entrepreneur with a strong track record of starting, building and leading successful drug discovery organizations. He is currently Venture Partner at Atlas Venture, an Advisor to Google Ventures, and Adjunct Professor at the Perelman School of Medicine, University of Pennsylvania. Copeland has brought 21 investigational new drugs into the clinic, five of which are today FDA-approved medicines. A Fellow of AAAS and the Royal Society of Chemistry, he has published widely on drug discovery, enzymology and related topics.